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Abstract
B7-H1 molecule increases the apoptosis of tumor-
reactive T lymphocytes and reduces their immuno-
genicity. Breast cancer is the second most common
cause of mortality after lung cancer. Direct evidence
linking B7-H1 with cancer has been shown in several
malignancies; however, its expression in breast cancer
has not been investigated. We used immunohisto-
chemistry to investigate the expression of the B7-H1
molecule in 44 breast cancer specimens and to study
its correlation with patients’ clinicopathological pa-
rameters. The expression of B7-H1 was shown in 22
of 44 patients and was not restricted to the tumor epi-
thelium (15 of 44, 34% in tumor cells), but was also
expressed by tumor-infiltrating lymphocytes (TIL; 18 of
44, 41%). Interestingly, intratumor expression of B7-H1
was significantly associated with histologic grade III–
negative (P = .012), estrogen receptor–negative (P =
.036), and progesterone receptor–negative (P = .040)
patients. In addition, the expression of B7-H1 in TIL was
associated with large tumor size (P = .042), histologic
grade III (P = .015), positivity ofHer2/neustatus (P = .019),
and severe tumor lymphocyte infiltration (P = .001).
Taken together, these data suggest thatB7-H1maybe an
important risk factor in breast cancer patients and may
represent a potential immunotherapeutic target using
monoclonal antibody against the B7-H1 molecule.
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Introduction
Breast cancer is the leading type of cancer affecting women
worldwide and is the second leading cause of mortality after
lung cancer [1]. Due to early detection, the majority of breast
cancer patients in western countries presents with early-
stage disease [2]; locally advanced breast cancer (LABC), a
very rare disease, does not exceed 5% of the total diagnosed
breast cancer cases. However, LABC is a very common dis-
ease in other countries such as Saudi Arabia (about 30%). It
affects women at very young ages and is distinctively associ-
ated with poor outcome. More than 40% of the cases admitted
to the hospital are already at very advanced stages [3,4]. The
extensive heterogeneity of breast cancer complicates the pre-
cise assessment of tumor aggressiveness; this makes thera-
peutic decisions difficult and treatment inappropriate in some
cases. Therefore, there is a strong need to identify parameters
that might predict the effectiveness of new treatments for each
patient, as well as to find new therapeutic options besides
chemotherapy that can be tailored to each group of patients.
Immunotherapy is currently the major focus, wherein thera-
peutic cancer vaccines may represent major alternatives and/
or adjuvant therapies besides chemotherapy [5]. Cancer cells
frequently express tumor antigens that, in principle, can be rec-
ognized by the patient’s immune system; however, resultant
immune responses are ineffective and often do not parallel
clinical tumor regression [6]. This raises an essential question
in tumor immunology: Why are neoplasms expressing tumor
antigens not eliminated by the patient’s own immune system?
A process named ‘‘tumor escape’’ has been suggested, and
several scenarios have been proposed to explain such phe-
nomenon [7,8]. In breast cancer, the presence of a massive
lymphocytic infiltrate should constitute immune responses
against the tumor; however, immune response seems to be
inefficient, and the tumor is able to evade it. It has been shown
that such tumor escape has resulted from the induction of
apoptosis in Fas-expressing activated lymphocytes by FasL-
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bearing breast cancer cells [9]. Classic B7-1 and B7-2
costimulatory molecules are known to be expressed in pro-
fessional antigen-presenting cells and provide positive sig-
nals to T lymphocytes through their interactions with CD28
molecule [10]. In addition, other regulatory molecules have
been recently discovered and shown to provide a negative
inhibitory signal to T lymphocytes. A cell surface glycoprotein
B7-H1 (also called PD-L1), which is expressed by antigen-
presenting cells, has been shown to induce T-lymphocyte
anergy and/or apoptosis after ligation to its T-lymphocyte re-
ceptor PD-1 [11–14].
Direct involvement of B7-H1 in the protection of cancer
cells from lysis by activated T lymphocytes has been dem-
onstrated [15]. The blockade of the protein or its ligand PD-1
by specific monoclonal antibodies has been shown to reverse
this effect and also to potentiate and improve the therapeu-
tic immunity of cancer [16–19]. Moreover, the expression of
B7-H1 has been described in several malignancies, including
ovary cancer, colon cancer, melanoma, and lung carcinoma
[13]; squamous cell carcinoma of the head and neck [16];
glioma [20]; non–small cell lung carcinoma [21]; renal cell
carcinoma [22]; and, recently, esophageal cancer [23]. How-
ever, its expression in breast cancer has not been well-
documented, except in five of six invasive ductal breast cancer
patients [24]. Furthermore, a strong link between B7-H1
expression by cancer cells or tumor-infiltrating lymphocytes
(TIL) and the patient’s clinicopathological status has been
shown in non–small cell lung carcinoma [21], renal cell carci-
noma [22], and esophageal cancer [23]. To our knowledge, no
such study has been carried out in breast cancer. In the
present study, we assessed the levels of the B7-H1 protein
in 44 breast cancer patients and correlated its expression with
the patients’ clinicopathological parameters. We found that
B7-H1 was expressed in 22 of 44 (50%) breast cancer pa-
tients, and that its expression was not restricted to epithelial
breast tissues but was also present in TIL. Moreover, we
showed great association between B7-H1 expression and
bad prognostic factors associated with high-risk patients.
Materials and Methods
Patients and Sample Collection
In this study, we concentrated on breast cancer patients
diagnosed with infiltrating ductal carcinoma (IDC), which
is the most common subtype of breast cancer, especially
amongwomen in theMiddle East [25]. Other tumor subtypes,
such as infiltrating lobular carcinoma and medullary carci-
noma, were excluded from this study because they are very
rare in this population [25]. Breast cancer specimens were
collected from primary tumors of 44 patients (median age,
45 years) who sought treatment and underwent surgery
(breast conservation surgery or total mastectomy) at the King
Faisal Specialist Hospital and Research Center from 2003
to 2005. Signed informed consent was obtained from all pa-
tients. Twenty-five patients were treated with neoadjuvant
chemotherapy prior to surgery, whereas 19 other patients
had no chemotherapeutic treatment before surgery. Pathol-
ogical tumor–node–metastasis staging was as follows:
stage I (n = 4), stage II (n = 19), and stage III (n = 20). One
patient had an unknown lymph node status (n = 1).
On excision of tissues by a surgeon, an anatomic pathol-
ogist obtaineda sample of the tumor tissue (denotedT) andan
adjacent normal breast tissue from the same breast having
the tumor (denoted N). Tissues from either T or N were fixed
in formalin and embedded in paraffin for routine histopatho-
logical analysis. Other pieces of tissues (N and T) were taken
and snap-frozen in liquid nitrogen after being embedded in
optimal cutting temperature (OCT) compound (Miles Labora-
tories, Elkhart, IN) and preserved at 80jC until processed.
All normal (N) breast tissueswere confirmedby the patholo-
gist to have normal morphology before the results were ana-
lyzed. Six normal samples showed evidence of tumor cell
infiltration and were designated as NA (indicative of no true
normal tissue). Normal breast tissues were also obtained
from two healthy women who underwent plastic surgery and
were designated as BP.
Breast Cancer Cell Lines and Fluorescence-Activated
Cell Sorter (FACS) Analysis
The MCF-7 and MDA-MB-231 breast cancer cell lines
were obtained from ATCC (Manassas, VA) and maintained
in culture using a complete DMEM. These cell lines were
used as negative and positive controls, respectively, for
B7-H1 expression. The MCF-7 and MDA-MB-231 cell lines
were stained with an anti –B7-H1-PE– labeled antibody
(ebioscience, San Diego, CA). After antibody staining, cells
were washed twice with cold phosphate-buffered saline
(PBS) containing 2% fetal bovine serum, suspended in
300 ml of PBS, and analyzed using FACS Scan (Immunocy-
tometry Systems; Becton Dickinson, San Jose, CA).
Immunohistochemistry
Routine hospital tests were evaluated by immunohisto-
chemistry on formalin-fixed, paraffin-embedded breast cancer
samples for Her2/neu, estrogen receptor, and progesterone
receptor status. HercepTest, a commercially available kit
(DakoCorp., Carpinteria, CA), was used for Her2/neu receptor
staining, according to the manufacturer’ instructions. A score
between 0 and 3+was recorded as illustrated inHercepTest kit
guidelines. For the purpose of this study, only 3+ sampleswere
considered Her2/neu–positive. The estrogen and proges-
terone receptors were stainedwith relevant specific antibodies
(Novocastra, Newcastle upon Tyne, UK).
For B7-H1 staining, fresh tissues that have been snap-
frozen in the OCT compound were sectioned, using a cryo-
tome (Shandon, Pittsburgh, PA), into 4 to 8 mm and adhered
to Superfrost slides (Fisherbrand, Pittsburgh, PA). After over-
night air drying, the sections were fixed in 4jC cold acetone
for 10 to 20 minutes, covered with aluminum foil, and stored
frozen at 80jC until use.
Before immunostaining, the sections were incubated in
PBS (Sigma, St. Louis, MO), pH 7.4, for a few minutes. En-
dogenous peroxidase was blocked for 15 minutes with 0.3%
hydrogen peroxide (Fisher Biotech, Fair Lawn, NJ) in PBS
containing 0.1% sodium azide. After two washes in PBS,
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sections were blocked with 10% goat serum (Dako Corp.) for
30 minutes, followed by addition of a primary antibody. Sec-
tions were stained using either a single-staining or a double-
staining procedure:
Single staining: B7-H1 primary antibody (MIH1 clone;
ebioscience) was used at 1:50 dilution and incubated
overnight at 4jC in a humidified chamber. After washing
thrice in PBS, the sections were stained for 30 minutes
at room temperature with Labeled Polymer (EnVision+)
horseradish peroxidase (HRP) detection kit (Dako Corp.).
After washing thrice with PBS, the sections turned red,
using the chromogen 3-amino-9-ethyl carbazole (Sigma),
and the sections were counterstained for 1 minute with
Harris hematoxylin (Acros Organics, Morris Plains, NJ).
Double staining: Two different species antibodies were
used at the same time. Mouse anti–B7-H1 antibody (1:10
dilution) was added to one of the following rabbit polyclonal
antibodies: pan-Cytokeratin (diluted 1:100; Dako Corp.),
CD3 (diluted 1:50; Dako Corp.), or CD8 (diluted 1:50; Ab-
cam, Cambridge, UK) and incubated overnight at 4jC in
a humidified chamber. Nonimmunized mouse isotype
matching for B7-H1 and normal rabbit IgG were used as
negative controls for other rabbit antibodies. On the follow-
ing day, the sections were washed thrice with PBS and
incubatedwith LabeledPolymer (EnVision+)HRPdetection
kit (Dako Corp.) mixed with swine anti-rabbit antibody at
1:50 (Dako Corp.) for 30 minutes at room temperature.
After washing in PBS, the substrates were added one at a
time, starting with Fast Red [for alkaline phosphatase (AP);
Dako Corp.] for 15 minutes followed by DAB+ (for HRP;
Dako Corp.). The sections were counterstained for 1 min-
ute with Harris hematoxylin (Acros Organics).
For double staining with B7-H1 and Foxp3, rabbit poly-
clonal anti-Foxp3 antibody (diluted 1:500; Abcam) was added
first for 1 hour at room temperature and washed thrice with
PBS followed by Labeled Polymer (EnVision+; anti-rabbit/
mouse) AP detection kit for 30 minutes at room temperature.
After washing thrice in PBS, the mouse anti–B7-H1 antibody
(1:10 dilution) was added and incubated for 2 hours at room
temperature in a humidified chamber. On the following day,
the sections were washed thrice with PBS and incubated
with Labeled Polymer (EnVision+; anti-mouse) HRP detec-
tion kit (Dako Corp.) for 30 minutes at room temperature.
After washing in PBS, the substrates were added one at a
time, starting with Fast Red (for AP; Dako Corp.) for 15 min-
utes followed by DAB+ (for HRP; Dako Corp.). The sections
were counterstained for 15 seconds with Instant Hematoxy-
lin (Shandon).
For double stainingwith B7-H1andCD4, twodifferent anti-
bodies with different mouse IgG isotypes were used at the
same time. The anti–B7-H1 antibody (IgG1 at 1:10 dilution)
was added to IgG2a CD4 antibody (Serotec, Raleigh, NC;
diluted 1:50) and incubated overnight in a humidified cham-
ber. On the following day, the sections werewashed thricewith
PBS, and two different isotype-specific secondary antibodies
(goat anti-mouse IgG1-HRP and goat anti-mouse IgG2a AP;
both from Southern Biotech, Birmingham, AL) were diluted
at 1:50 in PBS containing 10% AB serum (Sigma) and incu-
bated for 30 minutes at room temperature. After washing in
PBS, the substrates were added one at a time, starting with
Fast Red (forAP;DakoCorp.) for 15minutes followedbyDAB+
(for HRP; Dako Corp.). The sections were counterstained for
1minute with Harris hematoxylin (Acros Organics). Slides were
washed with distilled water, dried, and cover-slipped.
Thepercentages of tumor cells andTIL that stainedpositive
for B7-H1 were quantified at 5 to 10 increments by two in-
dependent pathologists who had no prior knowledge of patient
details. Diagnosis (type of breast cancer) was also confirmed
at the time of reading. The extent of TIL was assessed and
recorded as 0 (absent), 1 (focal), 2 (moderate), and 3 (severe).
Histologic Grade Evaluation
Histologic grades of breast cancer sections were
evaluated according to Scarff-Bloom-Richardson (SBR)
classification [26].
Statistical Analysis
Statistical analyses were used to determine the associa-
tion between B7-H1 expression and the patients’ clinicopath-
ological parameters. Relationships were assessed using
Fisher exact test. The significance level was set at .05, and
all P values were two-sided. The software package SAS 9.1
(SAS Institute, Cary, NC) was used for these analyses.
Results
B7-H1 Is Expressed Specifically in Tumor Tissues
To standardize the B7-H1 staining procedure, two breast
cancer cell lines (MCF-7 andMDA-MB-231) were stained with
the B7-H1-PE–labeled antibody and analyzed by flow cytom-
etry. The MDA-MB-231 cell line was positive for the mem-
brane expression of B7-H1 (95%),whereas theMCF-7 cell line
was completely negative (data not shown). We then adhered
cells to microscopic slides using cytospin and stained them
with an unlabeled B7-H1 antibody. MDA-MB-231 cells stained
positive, whereas a negative staining was obtained in the
MCF-7 cell line (Figure 1, A and B). Cytospin slides prepared
for the MCF-7 and MDA-MB-231 cell lines were used as
negative and positive controls, respectively, in the subsequent
immunohistochemical staining of patients’ tissue sections.
Of the 44 patients stained for the expression of B7-H1, 22
(50%)were found to be positive [15 of 44 (34%) in tumor cells].
The B7-H1 protein was expressed in 37% of patients receiv-
ing non-neoadjuvant chemotherapy, whereas its expression
has been detected in 60% of the patients treated with neo-
adjuvant chemotherapy (Table 1). More important, B7-H1–
positive sections were restricted only to tumor tissues (T), and
B7-H1–negative sections were expressed in all adjacent nor-
mal tissues (N). The expression was both membranous and/
or cytoplasmic. The intensity of B7-H1 staining ranged be-
tween + (low) and +++ (high) subjective scores, whereas the
percentage of tumor cells expressing B7-H1 ranged from 1%
to 50% of tumor cells in a given section (Table 1). Figure 1, C
and D, shows representative stained sections with the
B7-H1 antibody in normal tissues (N) and tumor tissues (T),
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respectively. Two normal breast tissues (BP) obtained during
plastic surgerywere found tobe negative for B7-H1expression
(data not shown). Double stainingwith the B7-H1 antibody and
pan-Cytokeratin antibody confirmed the expression of B7-H1
by tumor cells (Figure 1, E and F ). All isotype antibody–
stained slides were negative in both tumor and normal tissues
(data not shown).
B7-H1 Is Expressed in TIL
B7-H1was found to be present in TIL of 18 patients (41%),
in addition to its expression in tumor cells. The intensity of
B7-H1 staining ranged between + (low) and +++ (high), and
the percentage of TIL expressing B7-H1 ranged from 1% to
70% of TIL in a given section (Table 1). B7-H1 expression
by TIL in the sections was evaluated using double staining
of B7-H1 in CD3+ T lymphocytes (Figure 2, A and B). The ex-
pression of B7-H1 by TIL was not necessarily associated with
its presence in the tumor epithelium (only 11 of 18 patients
had expression in both). Moreover, the majority of TIL pre-
sented in the patient sections was generally of the CD4+
T-lymphocyte phenotype, with only a minority of CD8+ T lym-
phocytes (data not shown). B7-H1 expression in TIL was
highly associated with a CD4+ phenotype (Figure 2,C andD),
whereas its expression in CD8+ T lymphocytes was minimal
(Figure 2, E and F ). We have investigated whether CD4+
T lymphocytes expressing the B7-H1 molecule are of the
T-regulatory (T-reg) type. We used anti-Foxp3 antibody,
togetherwith the anti–B7-H1 antibody, to double-stain known
B7-H1+ TIL sections. We have found that B7-H1+ CD4 T
lymphocytes are negative for Foxp3 expression (Foxp3+ TIL
were negative for B7-H1 expression).
B7-H1 Expression Correlates with Clinicopathological
Parameters of Patients
Table 2 shows the correlation between the clinicopatho-
logical data of patients and B7-H1 expression in tumor cells
or in TIL. In tumor cells, the expression of B7-H1 was signifi-
cantly associatedwith histologic grade III–negative (P = .012),
estrogen receptor–negative (P = .036), and progester-
one receptor–negative (P = .040) patients. However, the
expression of B7-H1 in TIL was highly associated with large
tumor size (P = .042), histologic grade III (P = .015), positivity
Figure 1. Immunocytochemical staining of B7-H1–negative MCF-7 (A) and B7-H1–positive MDA-MB-231 (B) breast cancer cell lines confirm their phenotype, as
shown by FACS analysis. Photomicrographs, 400 magnification. Representative immunohistochemical staining in a B7-H1–positive breast cancer patient is also
presented. (C) A section from adjacent normal breast lobules (N) showing a negative reaction to B7-H1 antibody. (D) A section from the tumor tissue side (T)
showing a positive reaction to B7-H1 antibody. Note that the red-orange single stain represents B7-H1 expression. The localization of B7-H1 to epithelial tissues in
the tumor section (T) is presented by the double staining (arrow in F; blackish dark color) of pan-Cytokeratin (single red color) and B7-H1 (single brown color). (E)
Low magnification, 100. (F) High magnification, 540.
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of Her2/neu status (P = .019), and severe tumor lymphocyte
infiltration (P = .001). There was no significant correlation
with age, lymph node metastasis, and treatment with neo-
adjuvant chemotherapy.
Discussion
The balance between positive and negative signals is of great
importance in maximizing the ability of immune response to
defend the host while maintaining immunologic tolerance and
preventing autoimmunity [27]. In this respect, overexpression
of one of the costimulatory molecules by T lymphocytes or
antigen-presenting cells can have a deleterious effect on the
host immune system. This can result in either inhibition of the
immune system and permission of invasion by cancer cells, or
stimulation of the immune system to generate autoimmunity.
For example, although the expression of B7-H1 by microglial
cells is an important immune-inhibitory molecule capable of
downregulating T-lymphocyte activation in the central nervous
system to prevent immunopathological damage [28], expres-
sion of this molecule by malignant cells constitutes an impor-
tant immune escape mechanism in cancer [13,15,29].
In spite of remarkable advances in breast cancer (tradi-
tional, targeted, and neoadjuvant) therapies, approximately
40% of women still ultimately die of this disease [30]. Manipu-
lating the immune system to specifically recognize and de-
stroy tumor cells may represent a major alternative approach
for the management of cancer [5,6]. For example, passive
immunotherapeutic strategies, including the infusion of an
anti–Her2/neu monoclonal antibody (Herceptin), have been
shown to be effective in a subset of breast cancer patients
overexpressing theHer2/neu gene [31]. Nevertheless, active
immunotherapeutic strategies with cancer vaccines, wherein
the patient’s immune system is manipulated to specifically
eradicate breast tumor cells, may offer further theoretical ad-
vantages over other therapeutic strategies. However, the pres-
ence of an existing active immune tolerance and the antigenic
variability that arises from the genetic instability of breast
cancer limit the clinical efficacy of such therapeutic vaccina-
tion in patients with metastatic and advanced diseases [32].
Moreover, there is an extensive evidence for immune defects
in breast cancer patients, including a lower absolute number of
peripheral blood lymphocytes [33] and elevated numbers of
functionally immunosuppressive CD4+CD25+ T-reg lympho-
cytes in both peripheral blood and tumor microenvironment
[34]. In addition, dendritic cells obtained from the peripheral
blood and lymph nodes of patients with operable breast cancer
hada substantial decrease inmajor histocompatibility complex
class II and B7.2 expression, and IL-12 production [35], which
are essential elements for an effective immune response.
In addition, it has been shown that breast tumor cells
are able to evade the host immune system by induction of
Table 1. Expression of B7-H1 in Breast Cancer Cells and TIL.
B7-H1 Expression
Non-Neoadjuvant Chemotherapy Group Neoadjuvant Chemotherapy Group
Patient number N T % Tumor % TIL TIL Score Adjusted Score Patient number N T % Tumor % TIL TIL Score Adjusted Score
1 NA  0 20 –  1
2 –  1 21 – ++ 0 60 3 180
3 –  3 22 – ++ 30 0 1 0
4 NA  2 23 – +++ 30 0 1 0
5 –  1 24 –  1
6 – + 5 1* 1 1 25 – ++ 0 30 3 90
7 NA ++ 0 40 3 120 26 –  1
8 –  1 27 – + 1 0 2 0
9 – +++ 20 40 3 120 28 NA ++ 0 40 2 80
10 – +++ 5 50 3 150 29 – ++ 10 20 3 60
11 –  2 30 –  2
12 – + 50 70 3 210 31 NA + 5 0 1 0
13 –  1 32 – + 1 1 2 2
14 – +++ 30 50 2 100 33 –  2
15 –  3 34 – ++ 20 70 3 210
16 –  0 35 – +++ 50 2 2 4
17 –  0 36 –  0
18 –  1 37 – +++ 5 50 2 100
19 – ++ 0 30 1 30 38 – +++ 0 70 2 140
39 –  1
40 –  1
41 –  1
42 NA +++ 0 10 2 20
43 – +++ 10 5 1 5
44 –  1
B7-H1–positive 7/19 37% B7-H1–positive 15/25 60%
N, adjacent normal tissues; T, tumor tissues; NA, not available; , negative staining intensity; +, low staining intensity; ++, medium staining intensity; +++, high
staining intensity.
Adjusted score is calculated by multiplying the percentage of B7-H1–expressing TIL by the TIL score.
*The expression was checked in tumor cells and TIL, and the percentage of cells expressing B7-H1 was quantified in 5% to 10% increments by an anatomic
pathologist.
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apoptosis in Fas-expressing activated lymphocytes by FasL-
bearing breast cancer cells, highlighting the importance of
FasL as an immunoprotective molecule [9]. Another immuno-
regulatory molecule named B7-H1 has been shown in recent
years to be directly involved in the protection of cancer cells
from destruction by activated T lymphocytes [15]. A factor
such as lipopolysaccharide in the cancer microenvironment
has been shown to activate Toll-like receptor-4 on tumor
cells and to induce the synthesis of various proteins, including
B7-H1 [36]. The expression of this molecule has been de-
scribed in several malignancies [13,16,20–23] where a
strong link between its expression by cancer cells and the
patient’s clinicopathological status has been demonstrated
[21–23]. However, its expression in breast cancer has not
been well-investigated, except in six patients with IDC [24].
IDC is the most common subtype of breast cancer [30],
especially among women in the Middle East [25].
In the present investigation, we examine the expression
patterns of the B7-H1 protein in a larger number of subjects,
including 44 breast cancer patients with IDC, to correlate its
expression with patients’ clinicopathological data. Twenty-
two of 44 (50%) patients expressed the B7-H1 protein, in
which the expression was based on tumor cells, TIL, or both.
The percentage of cells expressing the B7-H1 was quantified
in 5% to 10% increments by an anatomic pathologist. B7-H1
was expressed in 60% of patients treated with neoadjuvant
chemotherapy, whereas its expression was 37% in chemo-
therapy-naive patients. Although its expression seems to be
higher in the neoadjuvant-treated patients, there was no sig-
nificant difference between the two groups. The relatively low
number of patients in each group makes it difficult to draw
a definitive conclusion. Nevertheless, the higher expression
of B7-H1 in patients with neoadjuvant chemotherapy could
simply be due to the fact that the patients receiving neo-
adjuvant chemotherapy usually have LABC (tumor size
z4 cm) and therefore have worse prognosis. In a relatively
large number of patients, Tringler et al. [37] reported a sig-
nificant correlation between breast cancer patients treated
with neoadjuvant chemotherapy and expression of another
T lymphocyte– inhibitory molecule named B7-H4. An impor-
tant implication of a high expression of B7-H1 in patients
treated with chemotherapy is the possibility that B7-H1–
expressing tumor cells are resistant to chemotherapy, leading
to tumor dormancy. It has been shown recently that long-term
persistent leukemic cells have increased B7-H1 expression
and resist cytotoxic T lymphocyte–mediated lysis [38].
Figure 2. Representative immunohistochemical staining shows the expression of B7-H1 by TIL. The expression of B7-H1 by TIL is shown using double stain-
ing (arrow in B; blackish dark color) for B7-H1 (single brown color) and CD3 (single red color), and using a nuclear (blue color) counterstain. (A) Low magnifica-
tion, 130. (B) High magnification, 540. The subsets of TIL expressing B7-H1 were identified using double staining (arrow in D) for B7-H1 (single brown color)
and CD4 (single red color). (C) Low magnification, 130. (D) High magnification, 540. The double staining of B7-H1 and CD8 molecules is shown. (E) Low
magnification, 130. (F) High magnification, 540.
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Interestingly, the expression of the B7-H1 protein was re-
stricted to tumor tissues (T), as evidenced by its complete ab-
sence in adjacent normal tissues (N) isolated from the same
patient’s breast, as well as in normal breast tissues taken
from patients undergoing plastic surgery. This observation is
very important especially when considering the B7-H1 mole-
cule as a potential therapeutic target in breast cancer. Anti–
B7-H1–specific monoclonal antibodies that can potentiate
and improve therapeutic immunity have already been inves-
tigated in other malignancies [16–19]. The expression of
B7-H1 in breast cancer was both membranous and/or cyto-
plasmic, and this is consistent with what has been found in
previous studies where other types of tumorswere examined.
Another important finding in this study is the expression
of B7-H1 by TIL. A similar finding has also been reported in
renal cell carcinoma [22]. B7-H1 inhibits anti-cancer immune
response. The mechanism by which the tumor-associated
B7-H1 protein inhibits anti-cancer immune response has
been shown to be interaction with its T-lymphocyte ligand
PD-1, leading to impairment in both cytokine production and
T-lymphocyte apoptosis [12,15,20,39]. However, the expres-
sion of B7-H1 by activated TIL can inhibit T-lymphocyte
clonal expansion either by reverse signaling process [40] or
by inhibition of other T lymphocytes by binding to PD-1 re-
ceptors in other T lymphocytes (T–T interaction), as has been
demonstrated very recently by Seo et al. [41]. The expres-
sion of B7-H1 by CD4+CD25+ T-reg lymphocytes has been
previously described by Greenwald et al. [42]. Schreiner
et al. [43] have recently shown that B7-H1–dependent im-
mune inhibition is mediated, in part, by CD4+CD25+ T-reg
lymphocytes. In addition, it has been demonstrated that both
peripheral blood and the tumor microenvironment of breast
cancer patients had elevated numbers of functionally immu-
nosuppressive T-reg [34]. We have shown in the present
work that B7-H1 is mainly expressed by CD4+ T lymphocytes
rather than by CD8+ T lymphocytes and is not of the T-reg
subtype. A possible interaction between T lymphocytes ex-
pressing B7-H1 and T-reg may exist, as has been shown re-
cently by Krupnick et al. [44].
We have also examined the relationship between the ex-
pression of B7-H1 in tumor cells or in TIL and the clinico-
pathological parameters of patients. Generally accepted
prognostic factors in breast cancer include the following:
patient age, tumor size, histologic grade, lymph node involve-
ment, and hormonal receptors status [45]. Our findings in-
dicate that B7-H1 correlates with important prognostic
factors, which are associated with high-risk patients. The ex-
pression of B7-H1 was significantly associated with large
tumor size (z4 cm; for TIL, P = .042), histologic grade III (for
tumor, P = .012; for TIL, P = .015), Her2/neu–negative status
(for TIL, P = .019), negative estrogen receptor (for tumor,
P = .036), and negative progesterone receptor (for tumor,
P = .040). There was no significant correlation with age
and lymph node metastasis. Similarly, a significant correla-
tion between high histologic grade and B7-H1 expression
was reported in renal cell carcinoma, whereas large tumor
size was marginal (P = .051) [22]. Concerning progester-
one status, Tringler et al. [37] have found a significant corre-
lation between B7-H4 and progesterone–negative patients,
similar to our findings. Both B7-H1 and B7-H4 molecules be-
long to the T lymphocyte– inhibitorymembers of the B7 family
[42]. Further studies are needed to reveal if this converse
relationship is due to molecular and/or clinicopathological
parameters, which may reflect a direct linkage between
progesterone status and expression of these molecules.
Thompson et al. [22] have found a correlation between
B7-H1 expression and lower survival rate among renal cell
carcinoma patients. B7-H1 has been shown to provide a
negative inhibitory signal to T lymphocytes when expressed
by antigen-presenting cells by inducing T-lymphocyte anergy
and/or apoptosis [11–14]. Therefore, it is possible that, by in-
hibiting the immune system, B7-H1 provides more advan-
tages for the tumor to grow. Alternatively, a lower survival
ratemaybedue to the associationof tumorswith higher growth
rate (large tumor size and high histologic grade) or lower
differentiation (high histologic grade, estrogen receptor–
negative status, and progesterone receptor–negative status),
which is known to lower the survival of cancer patients [45].
We recognize one drawback that relates to the relatively
low number of patients included in this current study. In
Table 2. Correlation between B7-H1 Expression in Tumor Cells and TIL and
the Clinicopathological Parameters of 44 Breast Cancer Patients.*
B7-H1 in Tumors Py B7-H1 in TIL P
+  + 
Age (years)
<40 5 (33)z 10 (67) .692 6 (40) 9 (60) .552
z40 8 (28) 21 (72) 9 (31) 20 (69)
Tumor size (cm)
<4 6 (25) 18 (75) .469 5 (21) 19 (79) .042
z4 7 (35) 13 (65) 10 (50) 10 (50)
Lymph node metastasis§
Negative 6 (40) 9 (60) .384 5 (33) 10 (67) .631
1–3 3 (30) 7 (70) 2 (20) 8 (80)
4–9 1 (9) 10 (91) 5 (45) 6 (55)
z10 2 (29) 5 (71) 3 (43) 4 (57)
Histologic grade (SBR)
II 3 (13) 20 (87) .012 4 (17) 19 (83) .015
III 10 (48) 11 (52) 11 (52) 10 (48)
Her2/neu status
Positive 7 (44) 9 (56) .119 9 (56) 7 (44) .019
Negative 6 (21) 22 (79) 6 (21) 22 (79)
Estrogen receptor status
Positive 7 (21) 26 (79) .036 10 (30) 23 (70) .356
Negative 6 (55) 5 (46) 5 (45) 6 (55)
Progesterone receptor status
Positive 4 (17) 20 (83) .040 7 (29) 17 (71) .450
Negative 9 (45) 11 (55) 8 (40) 12 (60)
Neoadjuvant chemotherapy
Without 5 (26) 14 (74) .682 6 (32) 13 (68) .759
With 8 (32) 17 (68) 9 (36) 16 (64)
Lymphocyte infiltration
None 0 (0) 4 (100) .280 0 (0) 4 (100) .001
Focal 5 (28) 13 (72) 2 (11) 16 (89)
Moderate 3 (25) 9 (75) 5 (42) 7 (58)
Severe 5 (50) 5 (50) 8 (80) 2 (20)
*In interpreting data and correlating them with clinicopathological parameters,
the 5% expression of cells was the cutoff point below which the number of
patients was considered as negative and above which the number of patients
was considered as positive.
yP values in italics represent significant data.
zNumbers inside parentheses are percentages of patients.
§One sample has unknown LN+ status.
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particular, the available antibody we used to stain breast
cancer sections is reliable only for immunohistochemical
staining of cryogenic sections and is not functional for stain-
ing of embedded tissues [13]. This will, therefore, not allow
for a retrospective study of archival paraffin-embedded ma-
terials. The collection of fresh frozen samples from breast
cancer patients at the King Faisal Specialist Hospital and
Research Center for this study was initiated in 2003.
Finally, the expression of the B7-H1 molecule in breast
cancer patients may represent an important additional
risk factor and may be considered as a potential immuno-
therapeutic target using monoclonal antibodies against this
molecule. Further studies are, however, warranted to dissect
the potential role of this B7-H1 molecule as a therapeutic,
prognostic, and/or diagnostic factor.
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